Diabetes Mellitus Clinical Trial
— USECAREOfficial title:
Exploring Acceptance and Outcomes of an ICT-based Self-management Support System for Community-dwelling Older Adults With Chronic Diseases and Informal Caregivers: USECARE Study Protocol
Verified date | July 2017 |
Source | Assuta Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the USECARE project is to improve and test SENACA, an ICT-based self-management support system for chronically ill patients and informal caregivers. 60 end-users will be instructed to use SENACA for approx. 3 months (in Israel and Norway). Amongst others, clinical and behavioural outcomes will be recorded. Additionally, SENACA's usability will be evaluated to determine its potential future scalability.
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | August 31, 2017 |
Est. primary completion date | August 31, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion community-dwelling older adults (primary end-users): - receive medical care for one or more of the following chronic diseases in hospital settings and outpatient clinics: 1. Chronic Heart Failure (CHF, New York Heart Association NYHA IIIIIa); 2. Diabetes Mellitus (DM, 6< HbA1c<9), 3. Chronic Obstructive Pulmonary Disease (COPD, GOLD I-II) 4. Special Orthopaedic Co-Morbidity (SOCM, after elective hip or knee replacement, health status temporarily destabilized respectively challenged, increased monitoring and formal/informal care). - having support of an informal caregiver that is aged 18 years or older - aged 50 years and older (primary end-users) Exclusion community-dwelling older adults (primary end-users): - known illiteracy (reading and writing difficulties) - lack of local language proficiency - current major mental illness of moderate to severe level - major acute illness or surgery in past 3 months (except elective hip / knee surgery for patients with SOCM) - participation in another intervention study Inclusion informal caregivers (secondary end-users): - aged 18 years or older - named by primary end-user as designated informal caregiver providing physical, emotional and/or social support for him or her Both inclusion criteria primary and secondary end-users: - written informed consent - adequate functional, sensory and cognitive abilities to use the SENACA system Both exclusion criteria primary and secondary end-users: - does not have a stable address of residence - no internet/computer access - inability to handle ICT-devices due to cognitive or functional disabilities |
Country | Name | City | State |
---|---|---|---|
Israel | Assuta Medical Center | Tel Aviv | |
Norway | University Hospital North Norway | Tromsoe |
Lead Sponsor | Collaborator |
---|---|
Assuta Medical Center | European Medical Network EMN AG, Institute for Health and Consumer Protection c/o University of Oslo, Faculty of Medicine, Norwegian Centre for Integrated Care and Telemedicine (NST), Open-Evidence c/o Universitat Oberta de Catalunya |
Israel, Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Level of and potential changes in technology acceptance in participants | Technology acceptance (usability) of system is measured by assessing participants' intention to use, perceived ease of use, perceived usefulness, technology experience, preference in using technology, errors, and user satisfaction. Instruments used are: Technology Acceptance Model (TAM), Post-Study System Usability Questionnaire (PSSUQ), all self-reported questionnaires. In addition, system errors will be reported (number and type of problems). | Up to three months | |
Secondary | Level of and potential changes in selected clinical outcomes of participants : BMI, weight, fasting glucose as well as HbA1c levels (sample) | Changes in selected clinical outcomes will be assessed with automated measurements via the intervention devices concerning body fat (fat proportion of body in %), body weight (in kg), blood pressure (systolic/diastolic in mmHg), pulse (per minute), SpO2 (in %) and fasting glucose (mmol). In Norway sample laboratory test will be conducted to determine levels of cholesterols (HDL, LDL in mmol), triglyceride (in mmol), HbA1c (mmol) and BNP (pg/ml). | Up to three months | |
Secondary | Level of and potential changes in health-related quality of life of participants assessed by EQ5D5L | Use of EQ-5DL a standardised instrument to measure health outcome and health-related quality of life. | Up to three months | |
Secondary | Level of and potential changes in uptake and usage of the SENACA intervention by participants | Automated recording of relative frequency of usage of SENACA's modules (usage of single components that are not mandatory), adherence to SENACA (Number of days within program from initiation to discontinuation (time to event), errors of system during intervention (number and type of technical problems occurring) | Up to three months | |
Secondary | Level of and potential changes in self-efficacy of participants | Measured with the Stanford Self-efficacy for managing chronic disease scale (SES6) | Up to three months | |
Secondary | Level of and potential changes in health-related behaviour: nutrition & alcohol consumption, smoking, physical activity | Self-reported questionnaires on weekly unit consumption (nutrition/alcohol), exercise (in Norway) and walking (minutes or hours/week), smoking behaviour (tobacco products, consumption per day), alcohol (units/week).Physical activity will be recorded automatically via pedometer (device). | Up to three months | |
Secondary | Level of and potential changes in eHealth Literacy in participants | eHealth Literacy is defined as the ability to read, use computers, search for information, understand health information, and put it into context.The eHealth Literacy Scale (eHEALS) as an 8-item measure will be used (self-reported questionnaire). | Up to three months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |